Rubicon Research shares touched a fresh high of Rs 1,808 on Monday, after the pharmaceutical company posted strong June quarter results.

The stock has been on a tear all through August. This rally took it well past its previous peak of Rs 1,686.45, set just four days earlier.

For the year so far, Rubicon has climbed over 160%, a run that stands out even more given the broader market has stayed largely flat. The results behind the move were strong across the board.

Revenue for Q1 FY27 grew 51.6% year on year to Rs 534 crore. Profit after tax jumped 95.8% to Rs 84.8 crore, up from Rs 43.3 crore a year earlier.

EBITDA rose 64.6% to Rs 131 crore, and margins expanded even though gross margins dipped a touch because of more outsourced manufacturing this quarter.

Rubicon makes and sells generic pharmaceutical products, mostly for the US market, and covers everything from research to production in-house.

Management said it now expects operating EBITDA margins to hold at 23% or higher for the full year, an upgrade from what it had guided earlier. A regulatory update helped too.

The company’s Pithampur site, bought last year, moved fast enough on its filing requirements to trigger a USFDA inspection by late June.

The audit wrapped up with just two procedural observations under a Form 483, and the company is now waiting on the final inspection report, with commercial ramp-up at the site targeted for early 2027.

Investors have read the smooth audit as a sign the company can bring new facilities up to speed quickly.

Trading was heavy through the session. Over 3 million shares changed hands combined on the NSE and BSE, well above the stock’s usual volume.

Rubicon Research shares closed the day at Rs 1,798.70, up 11.09% from the previous close. That takes the stock’s gain for the calendar year past 166%.

Unlock profitable opportunities every day! Tradz by EquityPandit provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Tradz by EquityPandit and start winning now!